Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) has been reported in ~5%-10% of critically ill COVID-19 patients. However, incidence varies widely (0%-33%) across hospitals, most cases are unproven, and CAPA definitions and clinical relevance are debated.

Methods

We reframed the debate by asking, what is the likelihood that patients with CAPA have invasive aspergillosis? We use diagnostic test performance in other clinical settings to estimate positive predictive values (PPVs) and negative predictive values (NPVs) of CAPA criteria for invasive aspergillosis in populations with varying CAPA incidence.

Results

In a population with CAPA incidence of 10%, anticipated PPV/NPV of diagnostic criteria are ~30%-60%/≥97%; ~3%-5% of teste

SUBMITTER: Clancy CJ 

PROVIDER: S-EPMC8903513 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature